Fibrobiologics' cell therapy CYMS101 significantly increased myelin production and promoted myelin repair in a mouse model of ...

Find out what happens to heart cells in space and how their adaptation could revolutionize heart disease treatment.

Mesoblast develops allogeneic products based on its proprietary remestemcel-L and rexlemestrocel-L mesenchymal lineage stromal and precursor cell platform technologies. Its allogeneic cellular ...

This fundraise comes following a private investment in public equity (PIPE) investment that the company closed in 2024, ...

Mesoblast filed a request for a Type B meeting during the last quarter, in line with previous guidance, and expects to have the meeting during this quarter. The meeting will be held under Mesoblast’s ...

Scientists created a stem cell-based method to produce high-quality mitochondria at scale, enabling effective treatments for ...

The board of directors of Grayson-Jockey Club Research Foundation announced that it has authorized expenditure of $2,693,312 ...

Terumo Blood and Cell Technologies has entered into a memorandum of understanding (MOU) with South Korea’s KBIOHealth to ...

Chaim Lebovits; President, Chief Executive Officer; Brainstorm Cell Therapeutics Inc. Alla Patlis; Interim Chief ...

Conference call and webcast at 8:30 a.m. Eastern Time today NEW YORK, March 31, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading ...

Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid ...

The following is a summary of “A Novel Molecular Regulatory Network in Bone Marrow Mesenchymal Stem Cells for Age-Related Osteoporosis,” published in the March 2025 issue of Clinical Endocrinology by ...